Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Liver Diseases

Free Subscription 10.10.2022 8 Am J Gastroenterol 5 Anticancer Res 1 Biochem Biophys Res Commun 3 BMC Cancer 10 Clin Res Hepatol Gastroenterol 1 Gastroenterology 1 Hepatology 4 J Gastroenterol Hepatol 3 J Hepatol 1 Oncogene 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 2 Semin Liver Dis 3 Transplant Proc 3 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. REAU N, Munoz SJ, Schiano T
   Liver Disease During Pregnancy.
   Am J Gastroenterol. 2022;117.
   PubMed        
   
   
2. HE K, Guo LL, Tang H, Peng X, et al
   A Freshwater Fish-Based Diet Alleviates Liver Steatosis by Modulating Gut Microbiota and Metabolites: A Clinical Randomized Controlled Trial in Chinese Participants With Nonalcoholic Fatty Liver Disease.
   Am J Gastroenterol. 2022;117:1621-1631.
   PubMed         Abstract available
   
   
3. JAMALI T, Raasikh T, Bustamante G, Sisson A, et al
   Outcomes of Exercise Interventions in Patients With Advanced Liver Disease: A Systematic Review of Randomized Clinical Trials.
   Am J Gastroenterol. 2022;117:1614-1620.
   PubMed         Abstract available
   
   
4. LIU C, Cao Z, Yan H, Wong YJ, et al
   A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study.
   Am J Gastroenterol. 2022;117:1605-1613.
   PubMed         Abstract available
   
   
5. LIAO KF, Hwang BF, Liu CS, Lai SW, et al
   Aspirin Use and the Risk of Liver Cancer.
   Am J Gastroenterol. 2022;117:1718.
   PubMed        
   
   
6. DEVARBHAVI H, Kurien SS, Raj S, Patil M, et al
   Idiosyncratic Drug-Induced Liver Injury Associated With and Without Drug Reaction With Eosinophilia and Systemic Symptoms.
   Am J Gastroenterol. 2022;117:1709-1713.
   PubMed         Abstract available
   
   
7. CAILES DB, Farouque AO, Majumdar AA, Koshy DAN, et al
   Title: Cardiac Dysfunction in the Pathogenesis of Hepatorenal Syndrome.
   Am J Gastroenterol. 2022 Sep 30. pii: 00000434-990000000-00535.
   PubMed        
   
   
8. LIN TAY PW, Ng CH, Lin SY, Chin YH, et al
   Placebo Adverse Events in Non-Alcoholic Steatohepatitis Clinical Trials. A Pooled Analysis of 2,944 Participants.
   Am J Gastroenterol. 2022 Sep 30. pii: 00000434-990000000-00528.
   PubMed         Abstract available
   
   

   
   Anticancer Res

9. UTSUMI M, Inagaki M, Kitada K, Tokunaga N, et al
   Lymphocyte-to-C-Reactive Protein Ratio Predicts Prognosis in Patients With Colorectal Liver Metastases Post-hepatic Resection: A Retrospective Study.
   Anticancer Res. 2022;42:4963-4971.
   PubMed         Abstract available
   
   
10. HANAKI T, Goto K, Morimoto M, Murakami Y, et al
    Surgical Administration of Indocyanine Green in Hepatectomy for Improved Bile Leakage Detection.
    Anticancer Res. 2022;42:4787-4793.
    PubMed         Abstract available
    
    
11. FUJIMOTO Y, Namisaki T, Takeda S, Murata K, et al
    Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.
    Anticancer Res. 2022;42:4895-4905.
    PubMed         Abstract available
    
    
12. HUANG J, Xi Q, Xiong J, Peng H, et al
    Micro RNA miR-1303 Promotion of Proliferation, Migration and Invasion of Human Liver Cancer Cells Is Enhanced by Low Talin 1 (TLN1) Expression.
    Anticancer Res. 2022;42:4715-4725.
    PubMed         Abstract available
    
    
13. NAGATA K, Sasaki R, Iwatsu S, Fukushima M, et al
    Long-term Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:5001-5007.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

14. KIM SQ, Mohallem R, Franco J, Buhman KK, et al
    Global landscape of protein complexes in postprandial-state livers from diet-induced obese and lean mice.
    Biochem Biophys Res Commun. 2022;629:40-46.
    PubMed         Abstract available
    
    

    
    BMC Cancer

15. IMAMURA T, Okamura Y, Ohshima K, Uesaka K, et al
    Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma.
    BMC Cancer. 2022;22:1046.
    PubMed         Abstract available
    
    
16. CHEN E, Yi J, Jiang J, Zou Z, et al
    Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
    BMC Cancer. 2022;22:1037.
    PubMed         Abstract available
    
    
17. WU G, Yang Y, Ye R, Yue H, et al
    Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma.
    BMC Cancer. 2022;22:1036.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

18. WANG J, Lun W, Shi W
    Effects of elevated bile acid levels on fetal myocardium in intrahepatic cholestasis of pregnancy, a retrospective study from a neonatal perspective.
    Clin Res Hepatol Gastroenterol. 2022;46:102013.
    PubMed         Abstract available
    
    
19. QIU JJ, Wei GF, Du JL, Guo J, et al
    Advances in the application of different anesthetic methods and drugs in interventional therapy for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101982.
    PubMed         Abstract available
    
    
20. STEENSIG K, Pareek M, Krarup AL, Sogaard P, et al
    Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - A nationwide register-based cohort study: Thromboembolism and bleeding in liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101952.
    PubMed         Abstract available
    
    
21. DING Y, Jiang L, Wang Q, Zhao W, et al
    The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.
    Clin Res Hepatol Gastroenterol. 2022;46:101951.
    PubMed         Abstract available
    
    
22. BOGOVIC N, Doenecke A, Hart C, Lurken L, et al
    Covid19 vaccination-associated portal vein thrombosis-An interdisciplinary clinical challenge.
    Clin Res Hepatol Gastroenterol. 2022;46:101932.
    PubMed         Abstract available
    
    
23. WARASNHE K, Ozcay F, Aydin HI, Ozgun G, et al
    A Novel Mutation in TRMT5 Associated with Idiopathic Non-Cirrhotic Portal Hypertension and Hepatopulmonary Syndrome: Case Report of Two Siblings.
    Clin Res Hepatol Gastroenterol. 2022 Apr 20:101928.
    PubMed         Abstract available
    
    
24. JAIN A, Sobotka LA, Wellner MR
    A rare mimicker of hepatocellular carcinoma: Syphilis.
    Clin Res Hepatol Gastroenterol. 2022;46:101919.
    PubMed        
    
    
25. BRAN DM, Fuks D, Lansier A, Gallois C, et al
    Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
    Clin Res Hepatol Gastroenterol. 2022;46:101920.
    PubMed        
    
    
26. LARREY E, Cluzel P, Rudler M, Goumard C, et al
    (TIPS for patients with early HCC: a bridge to liver transplantation).
    Clin Res Hepatol Gastroenterol. 2021 Aug 13:101790.
    PubMed         Abstract available
    
    
27. THABUT D, Weil D, Bouzbib C, Rudler M, et al
    Non-invasive diagnosis and follow-up of portal hypertension.
    Clin Res Hepatol Gastroenterol. 2022;46:101767.
    PubMed         Abstract available
    
    

    
    Gastroenterology

28. LI H, Zheng J, Xu Q, Yang Y, et al
    Hepatocyte Adenosine Kinase Promotes Excessive Fat Deposition and Liver Inflammation.
    Gastroenterology. 2022 Sep 28. pii: S0016-5085(22)01085.
    PubMed         Abstract available
    
    

    
    Hepatology

29. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
    Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
    Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

30. TONTIKIDOU C, Makri ES, Evripidou K, Goulis DG, et al
    Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2022;37:1853-1864.
    PubMed         Abstract available
    
    
31. LIU J, Qian Y, Yang F, Huang S, et al
    Value of prediction-model in distinguishing gallbladder adenoma from cholesterol polyp.
    J Gastroenterol Hepatol. 2022 Jun 24. doi: 10.1111/jgh.15928.
    PubMed         Abstract available
    
    
32. LIN CL, Tai CM, Huang JF, Liu CJ, et al
    The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    J Gastroenterol Hepatol. 2022;37:1901-1910.
    PubMed         Abstract available
    
    
33. FERNANDEZ M, Lokan J, Leung C, Grigg A, et al
    A critical evaluation of the role of iron overload in fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1873-1883.
    PubMed         Abstract available
    
    

    
    J Hepatol

34. ELFEKI MA, Singal AK
    The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?
    J Hepatol. 2022 Sep 30. pii: S0168-8278(22)03125.
    PubMed        
    
    
35. JOHN BV, Ferreira RD, Doshi A, Kaplan DE, et al
    Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)03002.
    PubMed         Abstract available
    
    
36. MAIWALL R, Deshmukh A, Sarin SK
    Reply to: "Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]".
    J Hepatol. 2022 Sep 13. pii: S0168-8278(22)03069.
    PubMed        
    
    

    
    Oncogene

37. LI T, Xie J, Shen C, Cheng D, et al
    Retraction Note: Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma.
    Oncogene. 2022 Sep 30. pii: 10.1038/s41388-022-02480.
    PubMed        
    
    

    
    PLoS One

38. TILLMANN HL, Suzuki A, Merz M, Hermann R, et al
    A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).
    PLoS One. 2022;17:e0271304.
    PubMed         Abstract available
    
    
39. ISHII M, Tominaga T, Nonaka T, Oyama S, et al
    Colon inflammatory index as a useful prognostic marker after R0 resection in patients with colorectal cancer liver metastasis.
    PLoS One. 2022;17:e0273167.
    PubMed         Abstract available
    
    
40. XU J, Ma H, Shan B
    Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.
    PLoS One. 2022;17:e0273163.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

41. TAO Z, Cui Y, Xu X, Han T, et al
    FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Proc Natl Acad Sci U S A. 2022;119:e2208844119.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

42. LEE S, Elton DC, Yang AH, Koh C, et al
    Fully Automated and Explainable Liver Segmental Volume Ratio and Spleen Segmentation at CT for Diagnosing Cirrhosis.
    Radiol Artif Intell. 2022;4:e210268.
    PubMed         Abstract available
    
    

    
    Semin Liver Dis

43. GOFTON C, Agar M, George J
    Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma.
    Semin Liver Dis. 2022 Sep 17. doi: 10.1055/a-1946-5592.
    PubMed         Abstract available
    
    
44. JUANOLA A, Ma AT, Pose E, Gines P, et al
    Novel biomarkers of AKI in cirrhosis.
    Semin Liver Dis. 2022 Oct 3. doi: 10.1055/a-1954-4136.
    PubMed         Abstract available
    
    

    
    Transplant Proc

45. LIVINGSTONE J, Raveh Y, Souki F, Shatz V, et al
    Multivisceral Transplant in a Patient With Portopulmonary Hypertension: A Case Report.
    Transplant Proc. 2022;54:1664-1670.
    PubMed         Abstract available
    
    
46. TIRNOVA I, Karatas C, Mecit N, Kanmaz T, et al
    Using Pericholedochal Varix Inflow for Complete Portal Vein Thrombosis in Living Donor Liver Transplantation: A Case Report.
    Transplant Proc. 2022 Jul 12. pii: S0041-1345(22)00394.
    PubMed         Abstract available
    
    
47. KARATAS C, Alim A, Yildirimoglu T, Tirnova I, et al
    Split Liver Transplant From Deceased Marginal Donor: A Case Report.
    Transplant Proc. 2022 Mar 10. pii: S0041-1345(22)00098.
    PubMed         Abstract available
    
    

    
    Transplantation

48. DODGE JL, Lee BT, Kassem ACZ, Biggins SW, et al
    The Conundrum of Patients With Compensated Cirrhosis Requiring Kidney Transplantation; Kidney Alone or Simultaneous Liver Kidney Transplantation.
    Transplantation. 2022 Sep 26. pii: 00007890-990000000-00171.
    PubMed         Abstract available
    
    
49. PHILIP G, Hookey L, Richardson H, Flemming JA, et al
    Alcohol-associated Liver Disease Is Now the Most Common Indication for Liver Transplant Waitlisting Among Young American Adults.
    Transplantation. 2022 Jun 1. pii: 00007890-990000000-00064.
    PubMed         Abstract available
    
    
50. JAMIL OK, Sandikci B, Faust N, Cotter TG, et al
    Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States.
    Transplantation. 2022 Jun 29. pii: 00007890-990000000-00093.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: